danicopan PNH
Selected indexed studies
- Long-term efficacy and safety of danicopan as add-on therapy to ravulizumab or eculizumab in PNH with significant EVH. (Blood, 2025) [PMID:39700502]
- Addition of danicopan to ravulizumab or eculizumab in patients with paroxysmal nocturnal haemoglobinuria and clinically significant extravascular haemolysis (ALPHA): a double-blind, randomised, phase 3 trial. (Lancet Haematol, 2023) [PMID:38030318]
- Danicopan: First Approval. (Drugs, 2024) [PMID:38528310]
_Worker-drafted node — pending editorial review._
Connections
No connections recorded yet.
Sources
- Addition of danicopan to ravulizumab or eculizumab in patients with paroxysmal nocturnal haemoglobinuria and clinically significant extravascular haemolysis (ALPHA): a double-blind, randomised, phase 3 trial. (2023) pubmed
- Danicopan: First Approval. (2024) pubmed
- Long-term efficacy and safety of danicopan as add-on therapy to ravulizumab or eculizumab in PNH with significant EVH. (2025) pubmed
- Safety and efficacy of danicopan in patients with paroxysmal nocturnal hemoglobinuria: a systematic review and meta-analysis. (2024) pubmed
- Navigating the Complement Pathway to Optimize PNH Treatment with Pegcetacoplan and Other Currently Approved Complement Inhibitors. (2024) pubmed
- Ravulizumab-danicopan combination therapy in PNH management. (2025) pubmed
- Complement inhibition in paroxysmal nocturnal hemoglobinuria: From biology to therapy. (2024) pubmed
- Advancements in complement inhibition for PNH and primary complement-mediated thrombotic microangiopathy. (2025) pubmed
- Paroxysmal Nocturnal Hemoglobinuria, Pathophysiology, Diagnostics, and Treatment. (2024) pubmed
- Breakthrough hemolysis in paroxysmal nocturnal hemoglobinuria throughout clinical trials: from definition to clinical practice. (2025) pubmed